|
Volumn 19, Issue 2, 2001, Pages 187-195
|
Health-related quality of life (HR-QOL) and regulatory issues: An assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval
a b c a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIHYPERTENSIVE AGENT;
ANTINEOPLASTIC AGENT;
ANTIVIRUS AGENT;
ALZHEIMER DISEASE;
ANGINA PECTORIS;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CLINICAL TRIAL;
DATA ANALYSIS;
DRUG APPROVAL;
EVALUATION;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE;
HEALTH ECONOMICS;
HEALTH STATUS;
HEART FAILURE;
HUMAN;
MEDICINAL PLANT;
METHODOLOGY;
NOMENCLATURE;
OSTEOARTHRITIS;
PARKINSON DISEASE;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RELIABILITY;
REVIEW;
RHEUMATOID ARTHRITIS;
STROKE;
VALIDATION PROCESS;
DRUG APPROVAL;
EUROPEAN UNION;
HUMANS;
QUALITY OF LIFE;
|
EID: 0035116858
PISSN: 11707690
EISSN: None
Source Type: Journal
DOI: 10.2165/00019053-200119020-00005 Document Type: Review |
Times cited : (85)
|
References (30)
|